Tempo Raises $220M in New Capital to Enhance AI & 3D Sensor Technology

Tempo the first home fitness system that uses advanced 3D sensors and AI to analyze users’ motion to provide a personal training experience—today announced $220 million in new funding.

Tempo notes the Series C round was led by SoftBank Vision Fund 2* with participation from new investor Steadfast Capital Ventures, and returning investors DCM, General Catalyst, Norwest Venture Partners, and Bling Capital. This brings Tempo’s funding to date to nearly $300 million.

Tempo will allocate the new funding toward the continued enhancement of its AI and 3D sensor technology to further expand its cutting-edge, real-time form feedback and personal guidance for users. The company also recently announced vast expansions across its hardware, software, and content offerings to best supplement the training experience and continue to deliver a full, at-home gym and personal trainer experience.

“Tempo was launched on the premise that the most advanced and versatile technology can unlock human potential by redefining the personal training experience. Today, our AI uses 3D sensors and is trained on over 5M workouts over 40K hours to give our users the most effective and personalized workouts possible,” said Moawia Eldeeb, Co-Founder and CEO of Tempo. “This new funding allows Tempo to further develop its AI to expand our class categories and content offerings.”

With its unique offering for at-home fitness, Tempo has gained significant momentum since launching in 2020. In the past year alone, Tempo saw its sales increase by 10 times and has seen 0% subscription cancellation.

“The fitness landscape has transformed dramatically as more consumers seek home fitness solutions. By providing personalized AI generated feedback through its computer vision technology, Tempo delivers the experience of working out with a personal trainer to consumers in their homes,” said Jeff Housenbold, Managing Partner, SoftBank Investment Advisers. “We’re excited to partner with Moawia and the Tempo team to support their ambition to help people progress in their fitness journeys at home.”

As the only complete yet incomparably compact and connected home training solution on the market, the Tempo Studio combines the hands-on guidance of a personal trainer, the motivation of a group fitness class, and premium design-forward equipment. After more than six years of developing Tempo’s flagship product, the company remains dedicated to providing the most efficient and personalized fitness experience to its community.

SourceTempo

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.